Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.

Slides:

Advertisements

Similar presentations

The genetic basis of myelodysplasia and its clinical relevance

Advertisements

Krug, U; Büchner, T; Berdel, W E; Müller-Tidow, C The Treatment of Elderly Patients With Acute Myeloid Leukemia Dtsch Arztebl Int 2011; 108(51-52): ;

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,

Identification of mutations prognostic of relapse after allogeneic transplantation and novel clone emergence at disease recurrence: implications for strategies.

Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw

New Findings in Hematology: Independent Conference Coverage

Clearance of ‘Driver-COSMIC’ mutations post-CR1 with persisting RUNX1_L56S is unlikely to contribute towards disease progression L . Rai1, T. Boneva1,

Clinically useful prognostic factors in acute myeloid leukemia

New Molecular Abnormalities Recognized in AML

NPM1, IDH1/2 and DNAH11 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by David Grimwade, Adam Ivey, and Brian J. P. Huntly

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan.

Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw

Gupta V, Tallman MS, Weisdorf DJ

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation by Jan Moritz Middeke,

Rapid Identification Of Compound Mutations In Patients With Ph-Positive Leukemias By Long-Range Next Generation Sequencing by Sandra Preuner, Renate Kastner,

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia by Philipp A. Greif, Annika.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling by.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Clinical Implications of Clonal Hematopoiesis

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Acute promyelocytic leukemia, microgranular variant

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but.

by Alexander Röth, Andreas Hüttmann, Russell P

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations by Jih-Luh.

A novel hierarchical prognostic model of AML solely based on molecular mutations by Vera Grossmann, Susanne Schnittger, Alexander Kohlmann, Christiane.

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia by Jose Roman-Gomez, Antonio.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Global approach to the diagnosis of leukemia using gene expression profiling by Torsten Haferlach, Alexander Kohlmann, Susanne Schnittger, Martin Dugas,

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia by Jochen Greiner, Yoko Ono, Susanne.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse by Alexander Höllein, Manja Meggendorfer, Frank Dicker,

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes by Kazuaki Yokoyama, Eigo Shimizu, Nozomi.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA by Nikola P. Konstandin, Friederike Pastore, Tobias Herold, Annika Dufour,

Emerging Importance of Mutational Analysis in Myelodysplastic Syndrome and Acute Myelogenous Leukemia Aaron T. Gerds, Matthew J. Walter, Bart L. Scott

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation by Wenbin Xiao, Maheetha.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

Methods applied in addition

Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia by Heiko Becker, Gabriele Greve, Keisuke Kataoka,

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia by Anne Sophie Kubasch,

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia by Sebastian.

Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic.

Impact of age on clinical risk scores in follicular lymphoma

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

How I treat T-cell acute lymphoblastic leukemia in adults

Cold agglutinin disease

Presentation transcript:

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne Amler, Maria C. Sauerland, Dennis Görlich, Stephanie Schneider, Nikola P. Konstandin, Annika Dufour, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Luise Hartmann, Philipp A. Greif, Michael Fiegl, Marion Subklewe, Stefan K. Bohlander, Utz Krug, Andreas Faldum, Wolfgang E. Berdel, Bernhard Wörmann, Thomas Büchner, Wolfgang Hiddemann, Jan Braess, and Karsten Spiekermann Blood Volume 128(5): August 4, 2016 ©2016 by American Society of Hematology

Overview of driver gene mutations identified by targeted sequencing in 664 AML patients. Klaus H. Metzeler et al. Blood 2016;128: ©2016 by American Society of Hematology

Analysis of variant allele frequencies (VAFs) of different driver gene mutations. Klaus H. Metzeler et al. Blood 2016;128: ©2016 by American Society of Hematology

Associations between driver gene mutations, cytogenetics, and patient characteristics. Klaus H. Metzeler et al. Blood 2016;128: ©2016 by American Society of Hematology

Subgroups of AML patients defined by mutually exclusive genetic alterations. Klaus H. Metzeler et al. Blood 2016;128: ©2016 by American Society of Hematology

Survival of patients with MRC intermediate-risk cytogenetics according to age group and DNMT3A and NPM1 mutation status. Klaus H. Metzeler et al. Blood 2016;128: ©2016 by American Society of Hematology

Survival of patients with MRC intermediate-risk cytogenetics according to the combined NPM1 and FLT3-ITD mutations status and DNMT3A and RUNX1 mutations. Klaus H. Metzeler et al. Blood 2016;128: ©2016 by American Society of Hematology

Survival of patients with MRC adverse-risk cytogenetics according to TP53 mutation status. Klaus H. Metzeler et al. Blood 2016;128: ©2016 by American Society of Hematology